Armin R Afshar, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · University of California San Francisco · UCSF Medical Group Business Services
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Afshar’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
State licence records
1 licence
- Illinois 125054718Temporary Medical Permit · since 2009 · expires 2011-06-30Specialty on the licence: OphthalmologyCancelledNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$52,494
Medicare paid this office $52,494 for 256 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 89 | $7,964 | $67 |
| Established patient complete exam of visual system | 81 | $4,604 | $52 |
| Imaging of retina | 114 | $4,009 | $23 |
| Return visit (30+ min) | 33 | $3,131 | $85 |
| Injection of drug into eye | 11 | $3,067 | $99 |
See all 17 services
| Established patient complete exam of visual system | 89 | $7,964 | $67 |
| Established patient complete exam of visual system | 81 | $4,604 | $52 |
| Imaging of retina | 114 | $4,009 | $23 |
| Return visit (30+ min) | 33 | $3,131 | $85 |
| Injection of drug into eye | 11 | $3,067 | $99 |
| Short return visit (20+ min) | 35 | $2,472 | $59 |
| Imaging of retina | 91 | $1,970 | $18 |
| 2d ultrasound scan of eye tissue and structures | 39 | $1,414 | $28 |
| 1d and 2d ultrasound scan of eye tissue and structures | 24 | $1,089 | $34 |
| Short return visit (20+ min) | 14 | $701 | $44 |
| 2d ultrasound scan of eye tissue and structures | 29 | $668 | $22 |
| Ultrasound scan of eye using water bath method | 20 | $625 | $30 |
| 1d and 2d ultrasound scan of eye tissue and structures | 22 | $508 | $21 |
| Ultrasound scan of eye using water bath method | 12 | $266 | $20 |
| Photography of content of eyes | 63 | $215 | $3 |
| Photography of the retina | 11 | $207 | $19 |
| Photography of content of eyes | 31 | $68 | $2 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
256 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 13% · Women 54% · Also on Medicaid 21% · Health risk score 1.53. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 65% · Coronary heart disease 26% · Chronic kidney disease 21% · Cancer 21% · Diabetes 20% · Atrial fibrillation 18% · Heart failure 14% · Depression 14% · Stroke 9% · COPD 8%.
The office billed $577,432, Medicare allowed $72,082 and paid $52,494; for 1,057 services of 42 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 256 | 1,057 | 74 | 1.53 | $577,432 | $52,494 |
| 2023 | 249 | 1,085 | 75 | 1.57 | $602,435 | $60,501 |
| 2022 | 273 | 1,255 | 74 | 1.42 | $725,515 | $72,963 |
| 2021 | 275 | 1,270 | 74 | 1.54 | $769,616 | $71,937 |
| 2020 | 260 | 1,158 | 74 | 1.78 | $737,829 | $78,773 |
| 2019 | 266 | 1,253 | 74 | 1.48 | $639,005 | $69,269 |
| 2018 | 321 | 1,558 | 74 | 1.50 | $858,313 | $97,706 |
| 2017 | 164 | 575 | 75 | 1.43 | $338,955 | $44,876 |
| 2016 | 87 | 266 | 71 | 1.35 | $219,709 | $30,465 |
| 2015 | 82 | 185 | 72 | 1.59 | $216,286 | $25,433 |
| 2014 | 110 | 189 | 70 | 1.60 | $157,027 | $26,307 |
| 2013 | 245 | 423 | 73 | 1.56 | $268,693 | $34,543 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Established patient complete exam of visual system | 146 | $14,341 | $65 |
| Injection of drug into eye | 23 | $7,528 | $88 |
| Imaging of retina | 169 | $7,091 | $21 |
| Return visit (30+ min) | 27 | $2,147 | $77 |
| 2d ultrasound scan of eye tissue and structures | 53 | $1,889 | $26 |
| Short return visit (20+ min) | 29 | $1,663 | $52 |
| 1d and 2d ultrasound scan of eye tissue and structures | 38 | $1,654 | $35 |
| New patient visit (45+ min) | 13 | $1,553 | $119 |
| Established patient problem focused exam of visual system | 26 | $1,349 | $41 |
| New patient complete exam of visual system | 12 | $958 | $80 |
| Ultrasound scan of eye using water bath method | 30 | $929 | $27 |
| Photography of the retina | 12 | $234 | $18 |
| Photography of content of eyes | 65 | $229 | $3 |
2022: 13 services
| Established patient complete exam of visual system | 141 | $13,804 | $62 |
| Imaging of retina | 183 | $7,300 | $21 |
| Injection of drug into eye | 20 | $6,819 | $81 |
| Return visit (30+ min) | 44 | $4,291 | $88 |
| Short return visit (20+ min) | 57 | $3,382 | $55 |
| Established patient problem focused exam of visual system | 42 | $2,874 | $44 |
| 1d and 2d ultrasound scan of eye tissue and structures | 46 | $2,081 | $34 |
| New patient complete exam of visual system | 28 | $1,860 | $66 |
| New patient visit (45+ min) | 14 | $1,671 | $119 |
| 2d ultrasound scan of eye tissue and structures | 41 | $1,422 | $25 |
| Ultrasound scan of eye using water bath method | 25 | $813 | $27 |
| Photography of the retina | 23 | $459 | $18 |
| Photography of content of eyes | 70 | $293 | $3 |
2021: 12 services
| Established patient complete exam of visual system | 179 | $17,427 | $67 |
| Injection of drug into eye | 34 | $11,816 | $88 |
| Imaging of retina | 194 | $8,210 | $22 |
| New patient complete exam of visual system | 45 | $3,877 | $86 |
| Established patient problem focused exam of visual system | 32 | $3,037 | $45 |
| 1d and 2d ultrasound scan of eye tissue and structures | 56 | $2,562 | $32 |
| 2d ultrasound scan of eye tissue and structures | 45 | $1,614 | $27 |
| Short return visit (20+ min) | 27 | $1,337 | $50 |
| Ultrasound scan of eye using water bath method | 24 | $762 | $25 |
| Return visit (30+ min) | 13 | $710 | $55 |
| Photography of the retina | 20 | $352 | $17 |
| Photography of content of eyes | 53 | $197 | $2 |
2020: 13 services
| Established patient complete exam of visual system | 165 | $15,791 | $66 |
| Injection of drug into eye | 22 | $7,406 | $95 |
| Imaging of retina | 166 | $6,757 | $22 |
| New patient complete exam of visual system | 50 | $4,317 | $86 |
| Established patient complete exam of visual system | 36 | $2,807 | $72 |
| Injection of drug into eye | 13 | $1,920 | $101 |
| Established patient problem focused exam of visual system | 26 | $1,846 | $42 |
| 1d and 2d ultrasound scan of eye tissue and structures | 29 | $1,428 | $42 |
| Imaging of retina | 45 | $1,276 | $24 |
| 2d ultrasound scan of eye tissue and structures | 27 | $1,152 | $27 |
| Ultrasound scan of eye using water bath method | 17 | $812 | $34 |
| Photography of the retina | 14 | $261 | $19 |
| Photography of content of eyes | 50 | $185 | $2 |
2019: 10 services
| Established patient complete exam of visual system | 183 | $20,331 | $65 |
| Injection of drug into eye | 24 | $8,807 | $99 |
| Imaging of retina | 180 | $8,093 | $23 |
| New patient complete exam of visual system | 54 | $4,741 | $88 |
| 1d and 2d ultrasound scan of eye tissue and structures | 57 | $4,740 | $52 |
| Established patient problem focused exam of visual system | 37 | $2,783 | $44 |
| Photography of the retina | 46 | $1,006 | $19 |
| Ultrasound scan of eye using water bath method | 22 | $901 | $25 |
| 2d ultrasound scan of eye tissue and structures | 21 | $901 | $33 |
| Photography of content of eyes | 69 | $259 | $2 |
2018: 12 services
| Established patient complete exam of visual system | 237 | $25,255 | $67 |
| Imaging of retina | 219 | $10,186 | $23 |
| Injection of drug into eye | 32 | $9,880 | $90 |
| 1d and 2d ultrasound scan of eye tissue and structures | 70 | $7,492 | $71 |
| New patient complete exam of visual system | 47 | $4,076 | $87 |
| Established patient problem focused exam of visual system | 54 | $3,887 | $45 |
| Removal of growth of eyelid lining, 1.0 cm or less | 13 | $1,680 | $129 |
| Photography of the retina | 55 | $1,207 | $19 |
| Ultrasound scan of eye using water bath method | 22 | $997 | $33 |
| Examination of eye by ophthalmoscope with retinal drawing | 28 | $950 | $15 |
| 2d ultrasound scan of eye tissue and structures | 14 | $704 | $37 |
| Photography of content of eyes | 55 | $268 | $3 |
2017: 11 services
| Established patient complete exam of visual system | 78 | $8,134 | $73 |
| Injection of drug into eye | 25 | $4,069 | $95 |
| 1d and 2d ultrasound scan of eye tissue and structures | 32 | $3,850 | $82 |
| Imaging of retina | 101 | $3,337 | $23 |
| New patient complete exam of visual system | 26 | $2,206 | $85 |
| Established patient problem focused exam of visual system | 29 | $1,911 | $48 |
| 2d ultrasound scan of eye tissue and structures | 12 | $843 | $50 |
| Photography of the retina | 24 | $608 | $19 |
| Examination of eye by ophthalmoscope with retinal drawing | 19 | $604 | $18 |
| Ultrasound scan of eye using water bath method | 12 | $497 | $33 |
| Photography of content of eyes | 17 | $75 | $3 |
2016: 7 services
| Established patient complete exam of visual system | 32 | $3,410 | $73 |
| 1d and 2d ultrasound scan of eye tissue and structures | 25 | $2,892 | $80 |
| New patient complete exam of visual system | 30 | $2,442 | $81 |
| Imaging of retina | 20 | $921 | $26 |
| Established patient problem focused exam of visual system | 11 | $538 | $45 |
| Photography of the retina | 20 | $448 | $21 |
| Photography of content of eyes | 13 | $42 | $3 |
2015: 5 services
| 1d and 2d ultrasound scan of eye tissue and structures | 26 | $2,666 | $83 |
| New patient complete exam of visual system | 26 | $2,265 | $87 |
| Established patient complete exam of visual system | 15 | $1,050 | $70 |
| Imaging of retina | 12 | $294 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $274 | $20 |
2014: 3 services
| Destruction of leaking blood vessels of retina using laser | 13 | $11,945 | $853 |
| Injection of drug into eye | 26 | $3,920 | $78 |
| Imaging of retina | 69 | $1,917 | $24 |
2013: 4 services
| Injection of drug into eye | 46 | $8,776 | $90 |
| Imaging of retina | 166 | $4,754 | $24 |
| Established patient complete exam of visual system | 25 | $1,742 | $67 |
| Examination of eye by ophthalmoscope with retinal drawing | 34 | $673 | $18 |
Medicaid work
$1,933 in 2024
Medicaid paid $1,933 for 57 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 42 | $1,270 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $663 |
| 2024 | 57 | 2 | 16 | $1,933 |
| 2023 | 86 | 2 | 16 | $4,496 |
| 2022 | 43 | 1 | 15 | $950 |
| 2021 | 108 | 2 | 18 | $3,785 |
| 2020 | 55 | 1 | 17 | $1,425 |
| 2019 | 43 | 3 | 16 | $1,284 |
| 2018 | 79 | 1 | 17 | $1,519 |
See the largest Medicaid services in earlier years
2023
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 40 | $3,322 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 46 | $1,173 |
2022
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 43 | $950 |
2021
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 29 | $1,981 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 79 | $1,804 |
2020
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 55 | $1,425 |
2019
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 16 | $498 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 13 | $418 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 14 | $367 |
2018
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 79 | $1,519 |
Drugs they prescribed that Part D paid
$6,940
Pharmacies billed $6,940 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
125 generic and 121 brand-name prescriptions · $6,940 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 83 | $3,360 | $40 |
| Neomycin-Polymyxin-Dexameth | 49 | $540 | $11 |
| Latanoprost | 13 | $332 | $26 |
| Polymyxin B Sul-Trimethoprim | 36 | $331 | $9 |
| Fluorometholone | 11 | $194 | $18 |
Year by year
| 2024 | 246 | 70 | None | 49% | $6,940 |
| 2023 | 235 | 57 | 6% (15) | 41% | $10,180 |
| 2022 | 200 | 57 | None | 55% | $11,899 |
| 2021 | 177 | 50 | 7% (13) | 64% | $15,965 |
| 2020 | 127 | 41 | None | 68% | $10,891 |
| 2019 | 73 | 27 | None | 64% | $5,486 |
| 2018 | 140 | 42 | None | 59% | $8,298 |
| 2017 | 64 | 22 | None | 58% | $5,060 |
| 2016 | 78 | 20 | None | 59% | $5,750 |
| 2015 | 76 | 23 | None | 64% | $4,713 |
| 2014 | 149 | 36 | None | 77% | $13,710 |
| 2013 | 155 | 43 | None | 72% | $8,001 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Prednisolone Acetate | 66 | $2,440 | $37 |
| Neomycin-Polymyxin-Dexameth | 41 | $597 | $15 |
| Polymyxin B Sul-Trimethoprim | 34 | $356 | $10 |
| Brimonidine | 14 | $91 | $6 |
| Hydrocodone-Acetaminophen | 14 | $88 | $6 |
2022: 7 drugs
| Prednisolone Acetate | 47 | $2,461 | $52 |
| Atropine Sulfate | 18 | $991 | $55 |
| Dorzolamide-Timolol | 23 | $312 | $14 |
| Neomycin-Polymyxin-Dexameth | 21 | $267 | $13 |
| Latanoprost | 22 | $220 | $10 |
| Polymyxin B Sul-Trimethoprim | 17 | $136 | $8 |
| Brimonidine | 16 | $80 | $5 |
2021: 4 drugs
| Prednisolone Acetate | 44 | $2,764 | $63 |
| Latanoprost | 20 | $218 | $11 |
| Polymyxin B Sul-Trimethoprim | 15 | $114 | $8 |
| Hydrocodone-Acetaminophen | 12 | $82 | $7 |
2020: 4 drugs
| Prednisolone Acetate | 34 | $1,977 | $58 |
| Atropine Sulfate | 17 | $1,327 | $78 |
| Neomycin-Polymyxin-Dexameth | 11 | $177 | $16 |
| Polymyxin B Sul-Trimethoprim | 18 | $134 | $7 |
2019: 2 drugs
| Fluorometholone | 13 | $1,377 | $106 |
| Prednisolone Acetate | 13 | $909 | $70 |
2018: 5 drugs
| Durezol | 24 | $4,195 | $175 |
| Prednisolone Acetate | 21 | $1,005 | $48 |
| Neomycin-Polymyxin-Dexameth | 13 | $191 | $15 |
| Polymyxin B Sul-Trimethoprim | 11 | $113 | $10 |
| Latanoprost | 13 | $75 | $6 |
2017: 2 drugs
| Prednisolone Acetate | 19 | $1,395 | $73 |
| Polymyxin B Sul-Trimethoprim | 13 | $109 | $8 |
2016: 3 drugs
| Durezol | 12 | $1,872 | $156 |
| Prednisolone Acetate | 12 | $1,051 | $88 |
| Polymyxin B Sul-Trimethoprim | 12 | $107 | $9 |
2015: 3 drugs
| Brimonidine | 11 | $1,312 | $119 |
| Prednisolone Acetate | 15 | $965 | $64 |
| Latanoprost | 12 | $205 | $17 |
2014: 3 drugs
| Brimonidine | 16 | $2,308 | $144 |
| Prednisolone Acetate | 14 | $1,014 | $72 |
| Latanoprost | 44 | $738 | $17 |
2013: 4 drugs
| Brimonidine | 23 | $2,724 | $118 |
| Latanoprost | 56 | $946 | $17 |
| Prednisolone Acetate | 20 | $622 | $31 |
| Dorzolamide-Timolol | 11 | $426 | $39 |
Money from drug and device companies
$26 in 2025
| 2025 | 1 | 1 | None | $26 |
| 2023 | 1 | 1 | None | $161 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Vabysmo | $26 | 1 payment
|
See the published payment
| Genentech USA | Meals · 2025-03-13 | Vabysmo | $26 |
See earlier years (2023)
2023: $161
| AbbVie | Ozurdex | $161 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2021 | Their institution | $105,218 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2022 | Their institution | $39,195 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2023 | Their institution | $26,580 |
| Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2022 | Their institution | $19,511 |
| Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2021 | Their institution | $16,299 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2024 | Their institution | $5,788 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1063742161
- Licence
- IL 125.054718Illinois 125054718: Cancelled
- Trained
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 2008
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 5841 S Maryland Ave, Mc 2114, Chicago, IL, 60637
- NPI first listed
- 2010-01-12
- NPI last updated
- 2010-01-12
This is when the NPI record was last certified, not a medical board exam.